- Home
- CHRS vs VBF Comparison
CHRS vs VBF Comparison
Compare CHRS & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- VBF
- Stock Information
- Founded
- CHRS 2010
- VBF 1970
- Country
- CHRS United States
- VBF United States
- Employees
- CHRS N/A
- VBF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- VBF Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- VBF Finance
- Exchange
- CHRS Nasdaq
- VBF Nasdaq
- Market Cap
- CHRS 84.2M
- VBF 176.7M
- IPO Year
- CHRS 2014
- VBF N/A
- Fundamental
- Price
- CHRS $0.85
- VBF $15.37
- Analyst Decision
- CHRS Buy
- VBF
- Analyst Count
- CHRS 3
- VBF 0
- Target Price
- CHRS $4.68
- VBF N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- VBF 45.5K
- Earning Date
- CHRS 08-07-2025
- VBF 01-01-0001
- Dividend Yield
- CHRS N/A
- VBF 5.18%
- EPS Growth
- CHRS N/A
- VBF N/A
- EPS
- CHRS N/A
- VBF N/A
- Revenue
- CHRS $272,251,000.00
- VBF N/A
- Revenue This Year
- CHRS N/A
- VBF N/A
- Revenue Next Year
- CHRS $99.43
- VBF N/A
- P/E Ratio
- CHRS N/A
- VBF N/A
- Revenue Growth
- CHRS 19.87
- VBF N/A
- 52 Week Low
- CHRS $0.66
- VBF $13.68
- 52 Week High
- CHRS $2.43
- VBF $16.27
- Technical
- Relative Strength Index (RSI)
- CHRS 53.52
- VBF 44.62
- Support Level
- CHRS $0.73
- VBF $15.35
- Resistance Level
- CHRS $0.96
- VBF $15.56
- Average True Range (ATR)
- CHRS 0.05
- VBF 0.11
- MACD
- CHRS 0.02
- VBF -0.02
- Stochastic Oscillator
- CHRS 53.92
- VBF 23.53
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.